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Available online 29 April 2016The m.3243A N G mutation is the most prevalent, disease-causing mitochondrial DNA (mtDNA) mutation. In a
national cohort study of 48 families harbouring the m.3243A N G mutation, we identiﬁed three families in
which the mutation appeared to occur sporadically within these families. In this report we describe these
three families. Based on detailedmtDNA analysis of three different tissues using two different quantitative pyro-
sequencing assays with sensitivity to a level of 1% mutated mtDNA, we conclude that them.3243A N Gmutation
has arisen de novo in each of these families. The symptomatic carriers presented with a variety of symptoms fre-
quently observed in patients harbouring the m.3243A N G mutation. A more severe phenotype is seen in the de
novo families compared to recent cohort studies, which might be due to reporting bias.
The observation that de novom.3243A N G mutations exist is of relevance for both diagnostic investigations and
genetic counselling. Firstly, even where there is no signiﬁcant (maternal) family history in patients with stroke-
like episodes, diabetes and deafness or other unexplained organ dysfunction, the m.3243A N G mutation should
be screened as a possible cause of the disease. Second, analysis of maternally-related family members is highly
recommended to provide reliable counselling for these families, given that the m.3243A N G mutation may
have arisen de novo.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In recent years, a large body of data concerning the inheritance of
mitochondrial disorders has been published [1–3]. Knowledge relating
to the mode of inheritance has great importance for both the diagnosis
and counselling of patients. Due to the involvement of the nuclear and
mitochondrial genomes, mitochondrial diseases can be transmitted in
a Mendelian manner, in the case of a nuclear aetiology, be maternally
transmitted in the case of primarymitochondrial DNA (mtDNA) defects
or they may occur sporadically [4].
In the case of single, large-scale mtDNA deletions such as those
observed in patients with the Kearns-Sayre Syndrome, Chronic
Progressive External Ophthalmoplegia or Pearson's Syndrome,AS, mitochondrial myopathy,
MIDD, maternally inherited di-
ged-red ﬁbres.
ren's Hospital, Radboud Center
lein 10, 6500 HB, PO BOX 9101,
t).
pen access article under the CC BY-Noccurrence is usually sporadic and recurrence in the offspring of fe-
male carriers is limited to 4% of the patients [5]. Our study focuses
on the m.3243A N G MTTL1 gene mutation, ﬁrst described by Goto,
Nonaka and Horai [6] as a cause of the mitochondrial myopathy, en-
cephalopathy, lactic acidosis and stroke-like episodes (MELAS) syn-
drome but which also causes maternally-inherited diabetes and
deafness (MIDD) [7]. Other clinical phenotypes include cardiac,
ocular, gastrointestinal and renal involvement. Them.3243A NGmu-
tation is the most prevalent, multi-system disease-causing mito-
chondrial DNA mutation, with a reported mutation prevalence of
between 7.59 and 236 per 100,000 [8–10].
A considerable number of case series and small cohorts have been
published describing the phenotypic expression of the m.3243A N G
mutation [11–17]. In contrast to what is seen for other mtDNA muta-
tions, the sporadic occurrence of the m.3243A N G mutation, with an
expressed phenotype, is rare with only four de novo cases published to
date [18–21] (see Table 1).
In our own cohort of Dutch m.3243A N G mutation carriers, we
identiﬁed three families where the m.3243A N G mutation appears
to have arisen de novo. The purpose of this paper is to document
these families, describing the probands' presentation in detailC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
An overview of all de novo reports of the m.3243A N G mutation.
Report: author
(year)
Gender
and age
at onset
Probands clinical sign & symptoms Heteroplasmy
levels
Number of tested maternal
family members and tested
tissues
Special characteristics
Yamamoto
(1995)
m, 21 years MELAS syndrome; SLE, mild deafness,
weakness,
Muscle: 89% 3; all studied in muscle. Mother was the de novo patient experiencing
MIDD. (muscle 79%, blood 10%)Blood: 36%
Campos et al.
(1996)
m, 2 years MELAS/MERRF overlap syndrome; epilepsy,
SLE, weakness, psychomotor delay
Muscle: 70% 4; all studied in blood, 1 studied
in muscle, 1 studied in hairBlood: 30%
Ko et al. (2001) m, 5 years MELAS syndrome; epilepsy, SLE, ataxia,
blurred speech, paralytic ileus,
Muscle: 54% 6; all studied in blood, hair and
buccal saliva
Mother was the de novo patient experiencing
mild deafness, (blood 11%, hair 27%, buccal
saliva 32%); the younger brother was a
dormant carrier. (blood 65%, hair 79%, buccal
saliva 70%)
Blood: 56%
Hair: 70%
Buccal saliva: 64%
Maassen et al.
(2002)
f, 8 years MIDD; bilateral deafness, diabetes,
hypertension, proteinuria
Blood: 18% 4; all studied in blood and
buccal salivaBuccal saliva: 55%
Patient 1
(this study)
m, 34 years MELAS syndrome; aphasia,
encephalopathy, deafness, SLE, epilepsy,
myopathy.
Muscle: 82% 16; all studied in blood, UEC
and buccal salivaBlood: 23%
UEC: 63%
Buccal saliva: 40
Patient 2
(this study)
m, 1 year Transient hypotonia, ataxia, ptosis and
ophthalmoplegia, motor retardation.
Improvement to normal at age 8.
Muscle: 23% 6; all studied in blood, UEC
and buccal saliva
Mother was the de novo patient, without
clinical symptoms. (UEC 6%, Muscle 5%,
undetectable in blood and buccal saliva)
UEC: 38%
Buccal saliva: 27%
Patient 3
(this study
m, 1 day Foetal distress, transient tachypneu of
the neonate, transient left ventricular
hypertrophy.
Muscle: 12% 3; all studied in blood, UEC
and buccal saliva
A sibling died post vaccination at age 4
months. No mutation load was found in
muscle.
Blood: 16%
UEC: 20%
Buccal saliva:16%
m=male, f = female, SLE = stroke-like episodes, UEC = urinary epithelial cells.
20 P. de Laat et al. / BBA Clinical 6 (2016) 19–24and highlighting the family members in whom the m.3243A N G
mutation was not detected. Maternal inheritance in a pedigree is
a trigger for clinicians to consider the presence of an mtDNA muta-
tion but even if there is no signiﬁcant family history in the mater-
nal line, the m.3243A N G mutation should be considered in
patients with symptoms consistent with the MIDD or MELAS
syndromes.2. Methods
All patients participated in the m.3243A N G mutation cohort study
at the Radboud Center for Mitochondrial Medicine [22]. 135 patients
from 48 families were included in this study. The study was approved
by the ethics committee of the Nijmegen–Arnhem region. Written in-
formed consent according to the Helsinki agreement was obtained
from all parents and patients ≥12 years.
Heteroplasmy levels were determined in urinary epithelial cells,
blood and buccal cells of all participants using Pyrosequencing™
technology (Pyrosequencing, Uppsala, Sweden) as described before
by Lowik, Hol, Steenbergen, Wetzels and van den Heuvel [23]. The
pyrosequencing assay of the m.3243A N G mutation in the mtDNA
(Genbank accession# NC_012920.1) has a precision of 1.5%, the pre-
cision relates to the correlation between independent measure-
ments of the same sample. A sensitivity of 4.5% has been quoted for
this technique, as determined by serial dilution of an m.3243A N G
positive sample in a sample containing wild type mtDNA, and by de-
termining the background signal +3× SD in a panel of 43 control
samples.
The tissue samples of patient II-3 of family 3 were collected within
2 h post-mortem. Samples were snap frozen using liquid nitrogen and
stored at−80 °C. DNAwas extracted using a Genomic DNA Puriﬁcation
Kit (Gentra,Mineapolis, USA), following themanufacturer's procedures.
In the families in which a de novo m.3243A N G mutation was
suspected, heteroplasmy levels in urinary epithelial cells from ﬁrst de-
gree family members were measured using a second pyrosequencing
assay with a sensitivity calculated at 1% as previously described by
Alston et al, [24].
The data of this study were submitted to the MITOMAP database
(www.mitomap.org).2.1. Family reports
2.1.1. Family 1
The proband (III-2, Fig. 1a) presented with aphasia and encephalop-
athy at the age of 34 years having experienced difﬁculty in speaking for
a few months with a history of hearing impairment since age 5. During
this episode of encephalopathy he spoke in short sentences andwas un-
able to respond to complex commands. There were no abnormalities in
the evaluation of cranial nerves, reﬂexes, motor skills or sensation. MRI
imaging showed abnormal signal intensities in both cortical and sub-
cortical areas of the left parieto-temporal lobe. MRI-spectroscopy dem-
onstrated elevated levels of lactic acid in the affected areas. Amuscle bi-
opsy was performed showing diminished ATP production and
decreased complex I activity (see Table 2). Unfortunately no histopath-
ological data are available. m.3243A N G mutation screening was per-
formed, revealing a high level of m.3243A N G mutation load (82%) in
muscle, conﬁrming the diagnosis of m.3243A N G related mitochondrial
disease. Assessment of m.3243A N G mutation levels in leucocytes, uri-
nary epithelial cells and buccal cells were 23%, 63% and 40%, respective-
ly. During follow-up, the patient developed epilepsy at the age of
35 years and diastolic dysfunction on echocardiography. He was myo-
pathic and unable to perform normal work. Lactate levels in blood
were elevated to an average level of 4.0 mmol/L (reference
b2.2 mmol/L). An extensive family study was performed. Family mem-
berswith symptoms that could be consistentwith them.3243A NGmu-
tation include a cousin (III-6) and her baby child (IV-6) who
experienced severe congenital hearing impairment, and the proband's
mother (II-3) who reported non-insulin dependent diabetes and mild
hearing impairment at the age of 71 years. A total of 16 familymembers
were tested for the presence of them.3243A N Gmutation, but this was
not detected in any other family member apart from the proband
(Fig. 1a). The underlying cause of the congenital hearing loss reported
by (III-6) and (IV-6) was investigated by whole exome sequencing,
and a nuclear-encoded mutation was identiﬁed which is likely to be
pathogenic.2.1.2. Family 2
The proband (IV-1, Fig. 1b) presented at the age of almost 2 years,
with neurological deterioration following a viral infection resulting in
Fig. 1. a–c Pedigrees of the three patients with a de novomutation. Fathers are not indicated in the pedigrees. The patients with a detectable m.3243A N G mutation load are indicated as
black squares and circles. The patients that were tested using pyrosequencing as earlier described by Lowik et al. (2005) are indicated in light grey shading; the patients that were
additionally tested using the more sensitive pyrosequencing assay described by Alston et al. (2011) are indicated with darker grey shading. a: Family 1; the proband is indicated as
individual III-2. Family members in whom the mutation was undetectable in urinary epithelial cells, leucocytes and buccal cells are; II-2, II-3, II-4, II-5, II-7, II-9, III-1, III-3, III-4, III-5, III-
6, III-7, III-8, III-9, III-10, IV-6. No further family members were available to participate in the study. Family members II-3 and III-1, mother and sister of the proband respectively, were
screened for m.3243 A N G heteroplasmy in urinary epithelial cells using the more sensitive pyrosequencing assay. b: Family 2; the proband is indicated as patient IV-1 however
individual III-3 (the proband's asymptomatic mother) is considered to be the de novo case following carrier testing. The m.3243A N G mutation was undetectable in urinary epithelial
cells, leucocytes and buccal cells of relatives denoted II-1, II-3, II-5, III-4 and III-7. The other family members did not participate in the study. Heteroplasmy was tested in urinary
epithelial cells from individual II-1, the proband's mother, using the more sensitive pyrosequencing assay. c: Family 3; the proband is indicated as patient II-4. Tested family members
in whom the mutation was undetectable in urinary epithelial cells, leucocytes and buccal cells are; I-1, II-1 and II-2. In all three family members, m.3243A N G mutation load in urinary
epithelial cells was tested using the more sensitive pyrosequencing assay. Patient II-3 died at the age of 4 months. Post mortem muscle and liver biopsies were screened and no
evidence of the m.3243A N G mutation was reported.
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lactate levels (5.5 mmol/L, reference b2.2 mmol/L) and abnormal signal
intensities in the parieto-occipital region on MRI. His neurological
symptoms improved after normalization and increase of his caloriﬁc in-
take. A muscle biopsy was performed, demonstrating diminished ATP
production, decreased complex I activity but no histopathological ab-
normalities (Table 2). Genetic testing revealed the m.3243A N G muta-
tion to be present at a level of 23% heteroplasmy in skeletal muscle.
Motor skill development was somewhat slow, requiring physiotherapy
but by the age of years he attendedmainstream school, and had normalmotor skills and strength. Heteroplasmy levels in urinary epithelial cells
and buccal cells were 38% and 27%, respectively. Six family members
were assessed; they were all in good health. Heteroplasmy analysis
showed a low level (6% mutation load) of m.3243A N G mutation in
the urinary epithelial cells from the mother (III-3), whereas the muta-
tion was undetectable in her blood and buccal cells. The patient's moth-
er (III-3) underwentmuscle biopsywhich showed a slightly diminished
ATP production, normal complex activities and no histopathological ab-
normalities suggestive of mitochondrial disease; heteroplasmy analysis
showed a 5% m.3243A N G mutation load in the muscle (see Table 2).
Table 2
Muscle biopsy results.
Patient Heteroplasmy
%
ATPa
(normal range)
%b Complex Ic
(normal range)
%b Complex IVc
(normal range)
%b Histopathology
Proband family 1 (III-2) 82% 5.8 (42.1–81.2) 13.8% 30 (100–401) 30% 809 (810–3120) 99.9% n.a.
Proband family 2 (IV-1) 23% 24.4 (42.1–81.2) 60.0% 49 (70–251) 70% 1269 (810–3120) 157% Normal
Mother of proband family 2 (III-3) 5% 13.8 (15.4–30.2) 90.0% 53 (47–154) 113% 1172 (470–1842) 249% Normal
Proband family 3 (II-4) 12% 10.4 (42.1–81.2) 24.7% 52 (70–251) 74.2% 759 (810–3120) 93.7% Normal
a ATP metabolism (nmol/h.mUCS).
b percentage of lower limit of normal range.
c Complex activity (mU/UCS); na = not available.
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grandmother underwent genetic testing in urinary epithelial cells and
did not harbour the m.3243A N G mutation (Fig. 1b). Patients III-1 and
III-2 did not consent to genetic testing, their case history did not suggest
any mitochondrial symptoms.
2.1.3. Family 3
The proband (II-4, Fig. 1c) was born at term with a birth weight of
4750 g (N97th centile). He was delivered by an emergency caesarean
section due to foetal distress and required short time respiratory
support because of transient tachypnea of the neonate. He had
hypoglycaemia that was treated with glucose infusions and elevated
lactate (pH 7.32, reference 7. 34–7.45; lactic acid 4.2 mmol/L, reference
b2.2 mmol/L) Left ventricular hypertrophy was seen on echocardio-
gram with no hemodynamic consequence. Muscle biopsy was per-
formed and showed a decrease of complex I and complex IV activities,
histopathological assays were normal (Table 2); mtDNA analysis re-
vealed them.3243A NGmutation at a heteroplasmy level of 12% inmus-
cle. Following a rapid recovery, the patient was discharged from the
hospital. At age ﬁvemonths, a second echocardiogram showed a normal
heart with no signs of hypertrophy or cardiomyopathy. Quantitative
mutation analysis of urinary epithelial cells, leucocytes and buccal
cells showedm.3243A N G heteroplasmy levels of 16%, 20% and 16%, re-
spectively. At six years of age the patient had no medical problems, in
particular no cardiomyopathy, fatigue or muscle weakness. DNA sam-
ples from his mother and siblings showed no detectable levels of the
m.3243A N Gmutation in urinary epithelial cells, leucocytes and buccal
cells (Fig. 1c). One of his siblings (II-3) died at four months of age from
dehydration following campylobacter gastro-enteritis complicated by
metabolic acidosis and liver failure. Post-mortemmuscle and liver biop-
sies showed a diffuse steatosis with no further abnormalities on either
conventional and electron microscopy nor following further biochemi-
cal andmolecular genetic testing; them.3243ANGmutationwas absent
in these post-mortem tissues.
3. Discussion
Genetic counselling in mitochondrial diseases caused by an mtDNA
mutation is complicated. With this report we provide additional infor-
mation regarding the inheritance of the m.3243A N G mutation.
There are only four previous reports of a sporadically occurring
m.3243A N G mutation, it is therefore of great signiﬁcance that we de-
scribe these new patients who most likely have de novo mutations.
We included 48 m.3243A N G mutation-positive families in our cohort
study; this is a follow-up study to our previously published national in-
ventory [22]. 37 of these families demonstrated maternal inheritance of
the m.3243A N Gmutation, whilst three families (8% of our cohort fam-
ilies) had a likely de novo occurrence of the m.3243A N G mutation, no
data were available concerning the family members in the remaining
seven families.
The clinical presentation of patients with a de novo m.3243A N G
mutation includes MELAS, MELAS/MERFF overlap, MIDD andcardiomyopathy. In recent cohort studies there is a predominance
of milder phenotypes, such as MIDD, amongst carriers of the
m.3243A N G mutation [16,22]. Interestingly, across all cases reported
to date, a MELAS phenotype was seen in the proband of ﬁve out of
eight families with a de novo appearance of the m.3243A N G mutation
(including the probands of families 1 and 2 from this study) [18–20].
One proband had a MIDD phenotype [21], and one proband had an iso-
lated cardiomyopathy (proband of family 3 of this study). There seems
to be a tendency towards amore severe phenotype in the index patients
of the families with a de novo appearance of them.3243A N Gmutation,
this could however also be the result of a bias in recognition of the phe-
notype, whereas a mildly affected individual would never be subjected
to mitochondrial DNA sequencing and these mild cases of de novo
m.3243A N G mutation may therefore be never found. In two of the
families with a de novom.3243A N Gmutation, the proband's mother
had either MIDD or an isolated deafness phenotype [18,20]. In fact,
these mothers are the individuals in whom the de novo mutational
event occurred, and their genetic diagnosis was only made following
the identiﬁcation of them.3243A NGmutation in their more severely
affected children.
An isolated incidence of an mtDNA mutation within a family can
have one of three causes, as stated byMaassen et al. [21]; 1.) other fam-
ily members in the maternal lineage harbour the mutation, but below
the detection limit, 2.) there is no biological relationship between the
proband and the other family members tested, 3.) a de novomutational
event has occurred23. We investigated the cause of the isolated
m.3243A N G mutation in the three families described in this report
using these three possibilities.
To investigate the possibility that the mutation is present below
the sensitivity of the assay, we used two different pyrosequencing tech-
niques as described previously [23,24]. The pyrosequencing assay de-
scribed by Lowik et al. has a sensitivity of 4.5% whereas the assay
described by Alston et al. has a higher sensitivity (1.0%). We tested
three different tissues for each available familymember, urinary epithe-
lial cells, leucocytes and buccal cells. No muscle was available of the
family members (except for patient II-3 of family 3), but previous stud-
ies have shown a good correlation between the m.3243A N G mutation
load in urinary epithelial cells andmuscle biopsy [25,26]. With sensitiv-
ities of 4.5% and 1.0% respectively for the two pyrosequencing assays,
the probability of multiple false-negative results are highly unlikely, it
is therefore unlikely that other family members in thematernal lineage
also carry the mutation below the detection limit. The family members
were also clinically assessed using the NMDAS for symptoms that
could be related to the m.3243A N G mutation. From a total of 23
adult relatives, two had hearing problems (including patient III-6
from family 1), two had diabetes mellitus (one insulin dependent),
three reported constipation, two relatives reported psychiatric com-
plaints and two reported visual abnormalities. No relatives reported
ataxia or myopathy. The results from the screening of non-invasive
familial samples suggest that the m.3243A N G mutation is unlikely
to be present below the detection threshold in our proposed de
novo m.3243A N G families.
23P. de Laat et al. / BBA Clinical 6 (2016) 19–24In order to investigate the second possibility of non-kinship as the
cause of isolated m.3243A N G occurrence, we obtained conﬁrmation
of kinship from the mothers within the families. Paternity testing was
not performed given that paternity is not relevant in establishing the in-
heritance of a mitochondrial DNA mutation. Having excluded kinship
and sensitivity issues,we conclude that there ismost likely a de novo ap-
pearance of the m.3243 A N G mutation in our three families.
The m.3243A N Gmutation has previously been detected in patients
with different haplotypes [8,27], indicating that de novo appearance of
them.3243A NGmutation has occurred frequently in the past. Although
the mechanism behind de novo appearance of the m.3243A N G muta-
tion is unknown, it is speculated that the mutational event is likely to
have occurred during oogenesis (in the mother's embryonic develop-
ment) or during early embryonic development of the proband [19].
These hypotheses are supported by our results given that each proband
harbours the mutation in tissues that originate from each of the three
primary germ cell layers.
This report detailing a further three cases harbouring a de novo
m.3243A N G mutation highlights the importance of screening for the
m.3243A N G mutation even if there is no signiﬁcant (maternal) family
history in a patientwithMELAS orMIDD symptoms. Moreover, a genet-
ic diagnosis of an m.3243A N Gmutation in an isolated patient does not
necessarily mean that others in the maternal lineage should automati-
cally be presumed to harbour themutation also. Despite the vast major-
ity (N90%) of m.3243A N Gmutation cases beingmaternally inherited, a
thorough family investigation should always be performed.
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